Saltar al contenido
Merck
  • National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation (2015-04-04)
Paul A Carpenter, Carrie L Kitko, Sharon Elad, Mary E D Flowers, Juan C Gea-Banacloche, Jörg P Halter, Flora Hoodin, Laura Johnston, Anita Lawitschka, George B McDonald, Anthony W Opipari, Bipin N Savani, Kirk R Schultz, Sean R Smith, Karen L Syrjala, Nathaniel Treister, Georgia B Vogelsang, Kirsten M Williams, Steven Z Pavletic, Paul J Martin, Stephanie J Lee, Daniel R Couriel
RESUMEN

The 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by the Ancillary Therapy and Supportive Care Working Group to support clinical research trials in chronic graft-versus-host disease (GVHD). Topics covered in that inaugural effort included the prevention and management of infections and common complications of chronic GVHD, as well as recommendations for patient education and appropriate follow-up. Given the new literature that has emerged during the past 8 years, we made further organ-specific refinements to these guidelines. Minimum frequencies are suggested for monitoring key parameters relevant to chronic GVHD during systemic immunosuppressive therapy and, thereafter, referral to existing late effects consensus guidelines is advised. Using the framework of the prior consensus, the 2014 NIH recommendations are organized by organ or other relevant systems and graded according to the strength and quality of supporting evidence.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Óxido de titanio (IV), nanopowder, 21 nm primary particle size (TEM), ≥99.5% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, anatase, nanopowder, <25 nm particle size, 99.7% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, anatase, powder, 99.8% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, rutile, powder, <5 μm, ≥99.9% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, anatase, powder, −325 mesh, ≥99% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, rutile, nanopowder, <100 nm particle size, 99.5% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, mixture of rutile and anatase, nanopowder, <100 nm particle size (BET), 99.5% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, mixture of rutile and anatase, nanoparticles, <150 nm particle size (volume distribution, DLS), dispersion, 40 wt. % in H2O, 99.5% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, rutile, ≥99.98% trace metals basis
Sigma-Aldrich
Titanium(IV) oxide, rutile, 99.995% trace metals basis
Sigma-Aldrich
Óxido de titanio (IV), contains 1% Mn as dopant, nanopowder, <100 nm particle size (BET), ≥97%
Sigma-Aldrich
Óxido de titanio (IV), nanowires, diam. × L ~100 nm × 10 μm
Sigma-Aldrich
Óxido de titanio (IV), nanowires, diam. × L ~10 nm × 10 μm
Sigma-Aldrich
Titanium(IV) oxide, rutile, <001>, (single crystal substrate), ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm
Sigma-Aldrich
(±)-CPP, solid